Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 4, 2014, Pages 306-312

  Beyazyildiz, Emrullah ^a   Acar, Uǧur ^b   Beyazyildiz, Özlem ^c   Pinarli, Ferda Alparslan ^d   Albayrak, Aynur ^d   Uǧurlu, Nagihan ^e   Tiryaki, Meral ^d   Delibaşi, Tuncay ^d  

^a Eye Clinic   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Ulucanlar Eye Research Hospital   (Turkey)

^d DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e Department of Pathology Dişkapi Yildirim Beyazit Research and Training Hospital ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; FLUORESCEIN; LOTEPREDNOL ETABONATE; PREDNISOLONE ACETATE; ROSE BENGAL; ANDROSTANE DERIVATIVE; BENZALKONIUM; PREDNISOLONE; PRESERVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRY EYE; INFLAMMATORY INDEX SCORING; INFLAMMATORY INFILTRATE; MALE; MICROSCOPY; NONHUMAN; RAT; SCHIRMER TEST; SCORING SYSTEM; STAINING; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DRY EYE SYNDROMES; INFLAMMATION; LACRIMAL FLUID; TOPICAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, TOPICAL; ANDROSTADIENES; ANIMALS; BENZALKONIUM COMPOUNDS; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; INFLAMMATION; MALE; PREDNISOLONE; PRESERVATIVES, PHARMACEUTICAL; RATS; RATS, WISTAR; TEARS;

EID: 84899982719     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0129     Document Type: Article

References (39)

1. International Dry Eye WorkShop. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul. Surf. 5:75-92, 2007.
2. Pflugfelder, S.C. Prevalence, burden, and pharmacoeco-nomics of dry eye disease review. Am. J. Manag. Care. 14:102-106, 2008.
3. Nichols, K.K., Foulks, G.N., Bron, A.J., et al. The international workshop on meibomiangland dysfunction-executive summary. Invest. Ophthalmol. Vis. Sci. 30:1922-1929, 2011.
4. Pflugfelder, S.C. Anti-inflammatory therapy of dry eye. Ocul. Surf. 1:31-36, 2003.
5. International Dry Eye WorkShop. Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workShop. Ocul. Surf. 5:163-178, 2007.
6. Na, K.S., Mok, J.W., Kim, J.Y., et al. Correlations between tearcytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest. Ophthalmol. Vis. Sci. 13:5443-5450, 2012.
7. Alhatem, A., Cavalcanti, B., and Hamrah, P. In vivo con-focal microscopy in dry eye disease and related conditions. Semin. Ophthalmol. 27:138-148, 2012.
8. Chen, W., Zhang, X., Zhang, J., et al. A murine model of dry eye induced by an intelligently controlled environmental system. Invest. Ophthalmol. Vis. Sci. 49:1386-1391, 2008.
9. Lin, Z., Liu, X., Zhou, T., et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol. Vis. 25:257-264, 2011.
10. Xiong, C., Chen, D., Liu, J., et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest. Ophthalmol. Vis. Sci. 49:1850-1856, 2008.
11. Zhu, L., Zhang, C., and Chuck, R.S. Topicalsteroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Mol. Vis. 18:1803-1812, 2012.
12. Paiva, C.S., and Pflugfelder, S.C. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq. Bras. Of-talmol. 71:89-95, 2008.
13. Lekhanont, K., Leyngold, I.M., Suwan-Apichon, O., et al. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea. 26:84-89, 2007.
14. Marsh, P., and Pflugfelder, S.C. Topical non-preserved methylprednisolone therapy of keratoconjunctivitis sic-cain Sjogren's syndrome. Ophthalmology. 106:811-816, 1999.
15. Sainz D.L.M.S., M., Simón, C.C., and Kabbani, O. Non-preserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca. Arch. Soc. Esp. Of-talmol. 75:751-756, 2000.
16. Pflugfelder, S.C, Maskin, S.L., Anderson, B., Chodosh, J., et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of kera-toconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol. 138:444-457, 2004.
17. De Paiva, C.S., Corrales, R.M., Villarreal, A.L., et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res. 83:526-535, 2006.
18. Pauly, A., Brignole, B.F., Labbe, A., et al. New tools for the evaluation of toxic ocular surface changes in the rat. Invest. Ophthalmol. Vis. Sci. 48:5473-5483, 2007.
19. Van Bijsterveld, O.P. Diagnostic test in the Sicca sydrome. Arc. Ophthalmol. 2:10-14, 1999.
20. Laria, C., Alio, J.L., and Ruiz, M.J.M. Combined non-steroidal therapy in experimental corneal injury. Ophthalmic. Res. 29:145-153, 1997.
21. Lemp, M.A. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 21:222-232., 1995.
22. McCabe, E., and Narayanan, S. Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry. 80:555-566, 2009.
23. Bartlett, J.D., Horwitz, B., Laibovitz, R., et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol. 9:157-165, 1993.
24. Baudouin, C. The pathology of dry eye. Surv. Ophthalmol. 45:211-220, 2001.
25. Ozcura, F., Dundar, S.A., Meteoglu, I., et al. Effects of long-term passive smoking on vascular endothelial growth factor and apoptosis markers expression in lens and corneal epithelial cells: an experimental study. Turk. J. Med. Sci. 39:843-848, 2009.
26. Pflugfelder, S.C. Antiinflammatory therapy for dry eye. Am. J. Ophthalmol. 137:337-342, 2004.
27. Yavuz, B., Bozdag, P.S., and Unlu, N. An overview on dry eye treatment: approaches for cyclosporin a delivery. Sci.-World J. 2012:194848, 2012.
28. Nagelhout, T.J., Gamache, D.A., Roberts, L., et al. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J. Ocul. Pharmacol. Ther. 21:139-148, 2005.
29. Avunduk, A.M., Avunduk, M.C., Varnell, E.D., et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol. 136:593-602, 2003.
30. De Paiva, C.S., Corrales, R.M., Villarreal, A.L., et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycy-cline. Invest. Ophthalmol. Vis. Sci. 47:2847-2856, 2006.
31. Foulks, G.N. The evolving treatment of dry eye. Ophthalmol. Clin. North Am. 16:29-35, 2003.
32. Comstock, T.L., and Decory, H.H. Advances in corticosteroid therapy for ocular inflammation: loteprednol eta-bonate. Int. J. Inflam. 2012:789623, 2012.
33. Mohamed, A.B., and Mohamed, I.K. Topical corticosteroid drops in the management of dry eye. Egypt. J. Hosp. Med. 39:181-188, 2010.
34. Glogowski, S., and Proksch, J. Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax ) in rabbits with corneal inflammation. Proceedings of the Association for Research in Vision and Ophthalmology Meeting Ft. Lauderdale, FL, USA, 2010.
35. Druzgala, P., Wu, W.M., and Bodor, N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr. Eye Res. 10:933-937, 1991.
36. Li, C., Song, Y., Luan, S., et al. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride. PLoS One 7:e33688, 2012.
37. McGinnigle, S., Naroo, S.A., and Eperjesi, F. Evaluation of dry eye. Surv. Ophthalmol. 57:293-316, 2012.
38. Barabino, S., and Dana, M.R. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest. Ophthalmol. Vis. Sci. 45:1641-1646, 2004.
39. Enŕiquez-de-Salamanca, A., Castellanos, E., Stern, M.E, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol. Vis. 16:862-873, 2010.